Need to keep on high of the science and politics driving biotech right now? Join to get our biotech publication in your inbox.
Good morning, and pleased birthday to me! Immediately, we see the Senate Appropriations Committee look to extend NIH funding, regardless of the Trump administration’s request to slash it. Additionally, Trump makes drug pricing calls for, and extra.
The necessity-to-know this morning
- Regeneron Prescription drugs mentioned the FDA rejected odronextamab, a therapy for follicular lymphoma. The company may also delay selections on two purposes searching for expanded use of its eye drug Elyea. All three purposes have been negatively impacted by points discovered by FDA inspectors at a Catalent contract manufacturing facility, Regeneron mentioned. The Catalent facility was just lately acquired by Novo Nordisk.
- Moderna and Regeneron reported second-quarter earnings.
Trump calls for drugmakers slash U.S. worth now
President Trump yesterday intensified his push to pressure pharmaceutical corporations to align U.S. drug costs with these in different rich nations, sending letters to 17 main corporations and demanding compliance by Sept. 29. The letters name for sweeping adjustments, STAT’s Elaine Chen writes, together with providing Medicaid and Medicare medicine at costs akin to the bottom ranges in nations a part of the Group for Financial Co-operation and Improvement which have a minimum of 60% of the U.S. GDP. The letter additionally referred to as to develop direct-to-consumer gross sales of high-rebate medicine, and repatriating overseas earnings.
